biotech · Fibrostenotic Crohn’s disease · liver cirrhosis · AGMB
Agomab Therapeutics NV
Agomab Therapeutics NV patent portfolio — 4 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Tel Aviv, USA
- Founded
- 2011
- Employees
- 20
- Programs
- 6
- Drugs
- 2
- Patents
- 4
Agomab Therapeutics NV patents
4 pharmaceutical patents indexed for Agomab Therapeutics NV. 0 expire within 24 months.
Agomab Therapeutics NV has 4 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12297186
Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5
granted -
US 12084504
Anti-MET antibodies and uses thereof
granted -
US 11834507
Anti-MET agonist antibody for use in the treatment of colorectal cancer
granted -
US 11098126
Anti-MET antibodies and uses thereof
granted
Frequently asked questions
How many patents does Agomab Therapeutics NV have?
4 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Agomab Therapeutics NV patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.